RPG Life Sciences FY26 Revenue Up 5.3% to ₹172.7 Crore

• RPG Life Sciences reported FY26 revenue of ₹172.7 crore, a 5.3% YoY increase, with an EBITDA margin of 24.4%.
• The company outlined a 6-pillar growth strategy focusing on scaling core brands, expanding its specialty portfolio, and strengthening its API business.
• ICRA reaffirmed the company's long-term rating at 'A+' with a stable outlook, citing a robust, debt-free capital structure and healthy cash flows.
• Significant ESG progress was reported, including a 48.5% reduction in carbon emissions and achieving a 7.3% women workforce representation.